Xencor, Inc. (FRA:XE9)
10.60
0.00 (0.00%)
Last updated: Jan 28, 2026, 8:12 AM CET
Xencor Revenue
Xencor had revenue of $21.00M USD in the quarter ending September 30, 2025, with 18.00% growth. This brings the company's revenue in the last twelve months to $150.13M, up 46.63% year-over-year. In the year 2024, Xencor had annual revenue of $110.49M, down -36.72%.
Revenue (ttm)
$150.13M
Revenue Growth
+46.63%
P/S Ratio
5.68
Revenue / Employee
$600.53K
Employees
250
Market Cap
726.68M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
| Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
| Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
| Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
| Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
| Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
| Dec 31, 2018 | 40.60M | -5.55M | -12.02% |
| Dec 31, 2017 | 46.15M | -62.87M | -57.67% |
| Dec 31, 2016 | 109.02M | 81.26M | 292.70% |
| Dec 31, 2015 | 27.76M | 18.24M | 191.62% |
| Dec 31, 2014 | 9.52M | -652.00K | -6.41% |
| Dec 31, 2013 | 10.17M | 648.00K | 6.80% |
| Dec 31, 2012 | 9.52M | 2.68M | 39.06% |
| Dec 31, 2011 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
| Berliner Effektengesellschaft AG | 174.56M |
Xencor News
- 12 days ago - Essex LLC Sells 1,200 Shares of Xencor Inc (XNCR) - GuruFocus
- 24 days ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Wallstreet:Online
- 24 days ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire
- 27 days ago - Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy - Seeking Alpha
- 4 weeks ago - Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 - Seeking Alpha
- 6 weeks ago - Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga
- 7 weeks ago - Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Business Wire
- 2 months ago - Truist Securities Initiates Coverage on Xencor (XNCR) with Buy Rating | XNCR Stock News - GuruFocus